menu
    • menu

    Company profile for Oncolytics Biotech

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Oncolytics BiotechCanada Flag
    Country
    Country
    Canada
    Address
    Address
    210, 1167 Kensington Crescent NW Calgary, Alberta T2N 1X7
    Telephone
    Telephone
    (403) 670-7377
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.oncolyticsbiotech.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/oncolytics-biotech-inc./
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oncolytics Biotech Updates Shareholders On Special Meeting
    Oncolytics Biotech Updates Shareholders On Special Meeting

    20 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251120748929/en/Oncolytics-Biotech-Provides-Update-on-Special-Meeting-of-Shareholders

    BUSINESSWIRE
    20 Nov 2025
    Share Share
    Oncolytics Biotech Aligns With FDA On Pelareorep Study
    Oncolytics Biotech Aligns With FDA On Pelareorep Study

    19 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251119471276/en/Oncolytics-Biotech-Aligns-with-FDA-on-Pivotal-Study-Design-for-Pelareorep-in-First-Line-Pancreatic-Cancer

    BUSINESSWIRE
    19 Nov 2025
    Share Share
    Oncolytics Biotech Forms Gi Tumor Advisory Board For Pelareorep
    Oncolytics Biotech Forms Gi Tumor Advisory Board For Pelareorep

    04 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251104294641/en/Oncolytics-Biotech-Establishes-Gastrointestinal-Tumor-Scientific-Advisory-Board-to-Advance-Pelareorep-as-a-Platform-Immunotherapy

    BUSINESSWIRE
    04 Nov 2025
    Share Share
    Oncolytics Biotech Files Prospectus For Shareholders' Meeting
    Oncolytics Biotech Files Prospectus For Shareholders' Meeting

    20 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/oncolytics-biotech-files-circularprospectus-for-special-meeting-of-shareholders-to-change-jurisdiction-of-incorporation-to-nevada-302588755.html

    PR NEWSWIRE
    20 Oct 2025
    Share Share
    Oncolytics Biotech Updates First-Line Pancreatic Cancer Study
    Oncolytics Biotech Updates First-Line Pancreatic Cancer Study

    29 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-update-for-potential-first-line-pancreatic-cancer-registration-study-302569436.html

    PR NEWSWIRE
    29 Sep 2025
    Share Share
    Oncolytics Biotech® Updates Safety Data for Pelareorep
    Oncolytics Biotech® Updates Safety Data for Pelareorep

    02 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/oncolytics-biotech-provides-updated-clinical-safety-data-for-pelareorep-including-across-multiple-gastrointestinal-tumors-302543591.html

    PR NEWSWIRE
    02 Sep 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search